Login or sign up
For business

Dolthera GmbH

4.1Β· 11 reviews
Average ratingGreat
4.1/ 5

Based on 11 reviews

536%
436%
327%
20%
10%
Ask AI

Ask AI about Dolthera GmbH

Generated with AI from 11 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Dominick Capozzi
Reviews 1

I recently availed the services of this company and I must say, I am highly impressed. Their website is easy to navigate and provides all the necessary information. The customer support team promptly addressed all my queries. I would recommend them to everyone!

Sybil Norris
Reviews 1

I am impressed with the services provided by Dolthera GmbH. They have a user-friendly website which makes it easy to navigate and find the information I need. The customer support team is always prompt in addressing any queries or concerns I have. Overall, a great experience!

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website β€” a simple way to convert your visitors into customers.

Get the widget for your site →

About Dolthera GmbH

Dolthera GmbH is a biopharmaceutical company that is developing an innovative class of nucleic-acid-based anti-inflammatory drugs.

These drugs, based on oligonucleotides that act as decoys for disease-related transcription factors are all directed against biologically validated targets in major chronic diseases with high unmet medical need. With this business concept and the underlying patent-protected technologies, AVONTEC won in 2003 the prestigious German Founders Award that is backed by McKinsey & Company.

Initially, the Company has chosen to focus its patented technology on chronic inflammatory respiratory system and skin diseases. AVONTEC currently has five programs in respiratory disease, skin disease, transplant rejection, cardiovascular disease and autoimmune disease under development. All these indications represent areas with high unmet medical need and strong commercial potential.